Perspective Therapeutics (NYSE:CATX) Research Coverage Started at HC Wainwright

HC Wainwright assumed coverage on shares of Perspective Therapeutics (NYSE:CATX) in a research note issued to investors on Thursday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $10.00 price objective on the stock. HC Wainwright also issued estimates for Perspective Therapeutics’ Q4 2024 earnings at ($0.24) EPS, Q1 2025 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.33) EPS and FY2025 earnings at ($1.19) EPS.

Several other brokerages have also recently issued reports on CATX. Royal Bank of Canada reaffirmed an “outperform” rating and set a $16.00 target price on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Bank of America lowered shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $24.00 to $5.00 in a research report on Monday, November 25th. Brookline Capital Management upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. Finally, Scotiabank began coverage on Perspective Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price target for the company. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $14.56.

Perspective Therapeutics Stock Performance

NYSE:CATX opened at $2.59 on Thursday. Perspective Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $19.05. The company has a fifty day moving average of $3.14 and a two-hundred day moving average of $7.26.

Hedge Funds Weigh In On Perspective Therapeutics

Large investors have recently modified their holdings of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Perspective Therapeutics by 19.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,150 shares of the company’s stock valued at $224,000 after buying an additional 11,472 shares during the period. Velan Capital Investment Management LP purchased a new stake in shares of Perspective Therapeutics in the 4th quarter valued at approximately $1,595,000. Squarepoint Ops LLC acquired a new position in shares of Perspective Therapeutics in the 4th quarter worth approximately $626,000. Wexford Capital LP acquired a new stake in Perspective Therapeutics in the 4th quarter valued at approximately $64,000. Finally, Two Sigma Advisers LP acquired a new stake in Perspective Therapeutics in the 4th quarter valued at approximately $484,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.